<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00644280</url>
  </required_header>
  <id_info>
    <org_study_id>LinLucentis</org_study_id>
    <secondary_id>NIH Grant # FVF4191S</secondary_id>
    <nct_id>NCT00644280</nct_id>
  </id_info>
  <brief_title>Ranibizumab in Preventing Failure of Ahmed Valve Glaucoma Surgery</brief_title>
  <official_title>Evaluation of Safety and Efficacy of Ranibizumab in Glaucoma Patients Treated With Filtration Tubes&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine whether ranibizumab therapy before and after tube insertion for glaucoma
      surgeries can maintain the patency of the tube and prevent scar formation, and increase the
      chances for a successful procedure compared to observation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, open-label, Phase I/II study of intravitreally administered ranibizumab
      for the treatment of tube patency in glaucoma patients.

      Thirty (30) patients with severe glaucoma requiring tubes will be randomized (2:1) to either
      ranibizumab or observation.

      Consented, enrolled subjects assigned to the treatment group will receive open-label
      intravitreal injection of 0.5 mg ranibizumab 1 week prior to tube insertion and then monthly
      x 2 more injections Sham intravitreal injections for the observation group will NOT be
      performed.

      Study periods:

      Study start date: May 1st, 2007 (estimated) Enrollment period: 6-8 months (estimated)
      Follow-up period: 6 months Study end Date: December 1st, 2010 (estimated)
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low recruitment
  </why_stopped>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tube Success at 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>Criteria for success at 6 months postoperatively was intraocular pressure (IOP) &lt; 18mmHg without the necessity for adjunctive medication for pressure or IOP &lt; 15mmHg with &lt;=1 adjunctive medication.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Significant Ocular Adverse Events</measure>
    <time_frame>6 months</time_frame>
    <description>Participants experiencing significant ocular adverse events, including endophthalmitis and rhegmatogenous retinal detachment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Ranibizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ranibizumab (0.5 mg in 0.05 mL) administered intravitreally at 3 time points: 9 days before Ahmed tube insertion for open-angle glaucoma, 1 month post-surgery, and 2 months post-surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of care Ahmed tube insertion for open-angle glaucoma without injections of Ranibizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab</intervention_name>
    <description>intravitreal injection of 0.5 mg ranibizumab 1 week prior to tube insertion and then monthly x 2 more injections</description>
    <arm_group_label>Ranibizumab</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ability to provide written informed consent and comply with study assessment for the
             full duration of the study.

          2. age â‰¥ 21

          3. diagnosis of glaucoma and determined to be candidate for therapy with tube insertion.

        Exclusion Criteria:

          1. pregnant or lactating females

          2. Persons on oral contraceptives and women of child-bearing age

          3. prior enrollment in the study

          4. any conditions the investigator believes would pose a significant hazard to the
             subject if the investigational therapy were initiated

          5. participation in another simultaneous medical investigation or trial

          6. history of active inflammatory, infectious, or idiopathic keratitis precluding view of
             anterior segment structures

          7. previous injections of ranibizumab in either eye.

          8. Persons on Plavix (clopidogrel bisulfate) and coumadin

          9. Persons with uncontrolled high blood pressure

         10. Persons with renal or liver disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Bhisitkul, M.D. , Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rajen U Desai</last_name>
    <role>Study Chair</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patricia Tam</last_name>
    <role>Study Director</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0730</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Desai RU, Singh K, Lin SC. Intravitreal ranibizumab as an adjunct for Ahmed valve surgery in open-angle glaucoma: a pilot study. Clin Exp Ophthalmol. 2013 Mar;41(2):155-8. doi: 10.1111/j.1442-9071.2012.02836.x. Epub 2012 Sep 4.</citation>
    <PMID>22712537</PMID>
  </results_reference>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2008</study_first_submitted>
  <study_first_submitted_qc>March 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2008</study_first_posted>
  <results_first_submitted>May 29, 2013</results_first_submitted>
  <results_first_submitted_qc>May 29, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 26, 2013</results_first_posted>
  <last_update_submitted>July 25, 2013</last_update_submitted>
  <last_update_submitted_qc>July 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 31, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Shan Lin</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Glaucoma,Ahmed Valve</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited from the University of California, San Francisco (UCSF) Glaucoma Service</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Ranibizumab</title>
          <description>Ranibizumab (0.5 mg in 0.05 mL) administered intravitreally at 3 time points: 9 days before Ahmed tube insertion for open-angle glaucoma, 1 month post-surgery, and 2 months post-surgery</description>
        </group>
        <group group_id="P2">
          <title>Usual Care</title>
          <description>Standard of care Ahmed tube insertion for open-angle glaucoma without injections of Ranibizumab</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ranibizumab</title>
          <description>Ranibizumab (0.5 mg in 0.05 mL) administered intravitreally at 3 time points: 9 days before Ahmed tube insertion for open-angle glaucoma, 1 month post-surgery, and 2 months post-surgery</description>
        </group>
        <group group_id="B2">
          <title>Usual Care</title>
          <description>Standard of care Ahmed tube insertion for open-angle glaucoma without injections of Ranibizumab</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Tube Success at 6 Months</title>
        <description>Criteria for success at 6 months postoperatively was intraocular pressure (IOP) &lt; 18mmHg without the necessity for adjunctive medication for pressure or IOP &lt; 15mmHg with &lt;=1 adjunctive medication.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ranibizumab</title>
            <description>Ranibizumab (0.5 mg in 0.05 mL) administered intravitreally at 3 time points: 9 days before Ahmed tube insertion for open-angle glaucoma, 1 month post-surgery, and 2 months post-surgery</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Standard of care Ahmed tube insertion for open-angle glaucoma without injections of Ranibizumab</description>
          </group>
        </group_list>
        <measure>
          <title>Tube Success at 6 Months</title>
          <description>Criteria for success at 6 months postoperatively was intraocular pressure (IOP) &lt; 18mmHg without the necessity for adjunctive medication for pressure or IOP &lt; 15mmHg with &lt;=1 adjunctive medication.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Significant Ocular Adverse Events</title>
        <description>Participants experiencing significant ocular adverse events, including endophthalmitis and rhegmatogenous retinal detachment</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ranibizumab</title>
            <description>Ranibizumab (0.5 mg in 0.05 mL) administered intravitreally at 3 time points: 9 days before Ahmed tube insertion for open-angle glaucoma, 1 month post-surgery, and 2 months post-surgery</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Standard of care Ahmed tube insertion for open-angle glaucoma without injections of Ranibizumab</description>
          </group>
        </group_list>
        <measure>
          <title>Significant Ocular Adverse Events</title>
          <description>Participants experiencing significant ocular adverse events, including endophthalmitis and rhegmatogenous retinal detachment</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ranibizumab</title>
          <description>Ranibizumab (0.5 mg in 0.05 mL) administered intravitreally at 3 time points: 9 days before Ahmed tube insertion for open-angle glaucoma, 1 month post-surgery, and 2 months post-surgery</description>
        </group>
        <group group_id="E2">
          <title>Usual Care</title>
          <description>Standard of care Ahmed tube insertion for open-angle glaucoma without injections of Ranibizumab</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>IOP reduction may be attributable to cataract surgery instead of or in addition to ranibizumab use. Further studies, with larger sample size and longer follow-up, are needed to evaluate safety and potential efficacy of intravitreal ranibizumab.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Shan C. Lin, MD</name_or_title>
      <organization>University of California San Francisco</organization>
      <phone>415-353-2608</phone>
      <email>lins@vision.ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

